Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fusion protein therapeutics - Altor BioScience

Next Previous
X
Search
Drug Profile

Research programme: fusion protein therapeutics - Altor BioScience

Alternative Names: 264scTCR/IgG1; ALT-802; ALT-804; Antiviral TCR - Ab; Antiviral TCR - Ck; IMPACT™ fusion proteins research programme - Altor BioScience; N-820; STAR-based therapeutics research programme - Altor BioScience; STAR-IMPACT; T cell receptor IgG1 fusion protein; T cell receptor IL-2 fusion protein

Latest Information Update: 28 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altor BioScience Corporation; Massachusetts General Hospital
  • Class Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Interleukin 15 receptor agonists; Interleukin 15 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Burkitt's lymphoma; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Viral infections

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for preclinical development in Burkitt's-lymphoma in USA
  • 01 Dec 2018 Preclinical trials in Burkitt's lymphoma in USA (unspecified route)
  • 01 Dec 2018 Pharmacodynamics data from a preclinical trial in Burkitt's lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top